摘要
目的:探讨利培酮联合少量氯丙嗪治疗精神分裂症合并支气管哮喘急性发作期的疗效与安全性。方法:将64例精神分裂症合并支气管哮喘急性发作期患者随机分为研究组(利培酮联合少量氯丙嗪组)和对照组(利培酮组)各32例,疗程均为6周。采用阳性和阴性症状量表(positive and negative symptom scale,PANSS)、临床总体印象量表及治疗中需处理的不良反应症状量表(treatment emergent symptom scale,TESS),在治疗前后分别评定疗效及不良反应。在治疗后第2周末评定哮喘的症状和体征消失的时间;在治疗前及治疗后第1周末分别测定两组的动脉血气分析结果、呼吸、心率变化情况。结果:2组在治疗第6周末PANSS总分、阳性症状分、阴性症状分及一般精神病理分均明显下降,与治疗前比较差异均有统计学意义(P<0.01)。研究组在治疗后第1周末减分率明显高于对照组,差异有统计学意义(P<0.05)。2组PANSS总分在治疗后第6周末差异无统计学意义(P>0.05)。2组总有效率差异无统计学意义(P>0.05)。研究组显效率为62.50%(20/32),与对照组显效率的40.63%(13/32)相比,差异有统计学意义(P<0.05)。在治疗后第2周末研究组的哮鸣音好转时间、临床哮喘症状消失时间、哮鸣音消失时间均快于对照组,差异均有统计学意义(P<0.05)。在治疗后第1周末研究组的二氧化碳分压、呼吸频数好转快于对照组,差异有统计学意义(P<0.05)。2组TESS总分在治疗后第1、6周末差异均无统计学意义(P>0.05)。研究组和对照组不良反应发生率分别为62.50%(20/32)和53.13%(17/32),差异无统计学意义(P>0.05)。结论:利培酮联合少量氯丙嗪治疗精神分裂症合并支气管哮喘急性发作期的疗效优于单用利培酮治疗,不良反应轻微。
Objective ：To explore of the efficacy and safety of risperidone combined with small doses of chlorpromazine in the treatment of schizophrenia with bronchial asthma at acute stage of seizures. Methods ： A total of 64 patients with schizophrenia with bronchial asthma at acute stage of seizures were randomly divided into study group（risperidone combined with a small does of chlorpromazine, n=32） and control group （risperidone, n=32） and continuous treatment was made for six weeks. Efficacy and adverse events were as- sessed with the positive and negative symptom scale（PANSS）, clinical global impression scale and treatment emergent symptom scale （TESS） before and after the treatment. Assessment on asthma symptoms and sign disappearing time at the end of the 2nd week after the treatment was conducted. Results of arterial blood gas analysis and changes of respiratory and heart rate of two groups were mea- sured before treatment and at the end of the first week after the treatment. Results：PANSS total scores,positive symptom scores, nega- tive symptom scores and general psychopathology scores of the two groups were significantly decreased at the end of the 6th week af- ter the treatment and were statistieaUy different compared with those before the treatment（P〈0.01 ）. Reduction rate was significantly higher in study group than in control group at the end of the first week after the treatment with statistical differences（P〈0.05）. There was no statistical difference in PANSS total scores between the two groups at the end of the 6th week after the treatment （P〉0.05）. There was no statistical difference in total effective rate between the two groups（P 〉0.05）. Marked effective rate of study group was 62.50% （20/32）, statistically higher than that of 40.63% （13/32） in control group （P〈0.05）. Reducing time of wheezing sound, disap- pearing time of clinical symptoms and disappearing time of wheezing sound were shorter in study group than in control group at the end of
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2013年第11期1365-1369,共5页
Journal of Chongqing Medical University
关键词
精神分裂症
支气管哮喘
急性发作期
利培酮
氯丙嗪
schizophrenia
bronchial asthma
acute stage of seizures
risperidone
chlorpromazine
